Evidence map›Paper›PMID 26935414›Full record

ArticleNanoscale2016

Anti-atherogenic effect of trivalent chromium-loaded CPMV nanoparticles in human aortic smooth muscle cells under hyperglycemic conditions in vitro.

Rituparna Ganguly, Amy M Wen, Ashley B Myer, Tori Czech, Soumyadip Sahu, Nicole F Steinmetz, Priya Raman

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Future of Nanoparticle-Directed Venous Therapy.Seminars in interventional radiology · 2017
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rituparna GangulyDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272-0095, USA. praman@neomed.edu and School of Biomedical Sciences, Kent State University, Kent, OH, USA.
Amy M WenDepartment of Biomedical Engineering, 10990 Euclid Avenue and Case Western Reserve University, Cleveland, OH, USA.
Ashley B MyerDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272-0095, USA. praman@neomed.edu.
Tori CzechDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272-0095, USA. praman@neomed.edu.
Soumyadip SahuDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272-0095, USA. praman@neomed.edu and School of Biomedical Sciences, Kent State University, Kent, OH, USA.
Nicole F SteinmetzDepartment of Biomedical Engineering, 10990 Euclid Avenue and Case Western Reserve University, Cleveland, OH, USA and Department of Radiology, 10990 Euclid Avenue and Case Western Reserve University, Cleveland, OH, USA and Department of Materials Science and Engineering, 10990 Euclid Avenue and Case Western Reserve University, Cleveland, OH, USA and Department of Macromolecular Science and Engineering, 10990 Euclid Avenue and Case Western Reserve University, Cleveland, OH, USA and Case Comprehensive Cancer Center, 10990 Euclid Avenue and Case Western Reserve University, Cleveland, OH, USA.
Priya RamanDepartment of Integrative Medical Sciences, Northeast Ohio Medical University, 4209 State Route 44, Rootstown, OH 44272-0095, USA. praman@neomed.edu and School of Biomedical Sciences, Kent State University, Kent, OH, USA.
Kent State University · USNortheast Ohio Medical University · USCase Comprehensive Cancer Center

Funding

Drug Delivery to Thrombotic Cardiovascular DiseaseR21HL121130 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI STEINMETZ, NICOLE FRANZISKA · 2015 to 2016
$416k
Hemostasis-Independent targeted treatment of thrombosisF31HL129703 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI WEN, AMY · 2015 to 2015
$13k
NHLBI NIH HHS F31 HL129703NHLBI NIH HHS R21 HL121130
6 · The paper itself

Abstract

Atherosclerosis, a major macrovascular complication associated with diabetes, poses a tremendous burden on national health care expenditure. Despite extensive efforts, cost-effective remedies are unknown. Therapies for atherosclerosis are challenged by a lack of targeted drug delivery approaches. Toward this goal, we turn to a biology-derived drug delivery system utilizing nanoparticles formed by the plant virus, Cowpea mosaic virus (CPMV). The aim herein is to investigate the anti-atherogenic potential of the beneficial mineral nutrient, trivalent chromium, loaded CPMV nanoparticles in human aortic smooth muscle cells (HASMC) under hyperglycemic conditions. A non-covalent loading protocol is established yielding CrCl3-loaded CPMV (CPMV-Cr) carrying 2000 drug molecules per particle. Using immunofluorescence microscopy, we show that CPMV-Cr is readily taken up by HASMC in vitro. In glucose (25 mM)-stimulated cells, 100 nM CPMV-Cr inhibits HASMC proliferation concomitant to attenuated proliferating cell nuclear antigen (PCNA, proliferation marker) expression. This is accompanied by attenuation in high glucose-induced phospho-p38 and pAkt expression. Moreover, CPMV-Cr inhibits the expression of pro-inflammatory cytokines, transforming growth factor-β (TGF-β) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), in glucose-stimulated HASMCs. Finally glucose-stimulated lipid uptake is remarkably abrogated by CPMV-Cr, revealed by Oil Red O staining. Together, these data provide key cellular evidence for an atheroprotective effect of CPMV-Cr in vascular smooth muscle cells (VSMC) under hyperglycemic conditions that may promote novel therapeutic ventures for diabetic atherosclerosis.

Indexed as

ComovirusAortaAtherosclerosisAzo CompoundsCell ProliferationCells, CulturedChloridesChromium CompoundsCytokinesDrug Delivery SystemsGlucoseHumansHyperglycemiaLipidsMicroscopy, Electron, TransmissionMicroscopy, FluorescenceAzo CompoundsChlorideschromic chlorideChromium Compoundschromous chlorideCytokinesGlucoseLipidsNF-kappa Boil red OProliferating Cell Nuclear AntigenTransforming Growth Factor beta

Identifiers

PMID26935414
PMCPMC5136293
OpenAlexW2280878449

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.